DOI:10.2214/AJR.06.0171
AJR 2006; 187:1124-1128
© American Roentgen Ray Society
PET/CT Characterization of Fibroosseous Defects in Children: 18F-FDG Uptake Can Mimic Metastatic Disease
Geoffrey S. Goodin1,2,
Barry L. Shulkin1,
Robert A. Kaufman1,2,3 and
M. Beth McCarville1,2
1 Division of Diagnostic Imaging, Department of Radiological Sciences, MS 210,
St. Jude Children's Research Hospital, 332 N Lauderdale St., Memphis, TN
38105-2794.
2 Department of Radiology, University of Tennessee Health Science Center,
Memphis, TN 38163.
3 Department of Pediatrics, University of Tennessee Health Science Center,
Memphis, TN 38163.
Received February 1, 2006;
accepted after revision March 30, 2006.
Supported in part by the American Lebanese Syrian Associated Charities
(ALSAC).
Address correspondence to M. B. McCarville
(beth.mccarville{at}stjude.org).
Abstract
OBJECTIVE. The purpose of this study was to characterize the
anatomic appearance and metabolic activity of nonossifying fibromas, fibrous
cortical defects, and cortical desmoids on PET/CT images.
CONCLUSION. Over a 14-month period, we identified eight nonossifying
fibromas, four fibrous cortical defects, and two cortical desmoids in 330
children who underwent PET/CT for the evaluation of a known or suspected
malignancy. CT, conventional radiography, MRI, or clinical follow-up was used
to confirm the diagnoses of these fibroosseous lesions. Eleven of the 14
children underwent multiple PET/CT examinations; thus, 34 studies were
included. The lesions showed variable metabolic activity as indicated by
18F-FDG uptake: 19 PET/CT examinations showed lesions with mild
18F-FDG uptake, eight showed moderate 18F-FDG uptake,
and seven showed intense uptake. When PET reveals metabolically active osseous
abnormalities in children who are at risk for bone metastases, benign
fibroosseous lesions should be considered in the differential diagnosis before
additional diagnostic procedures are undertaken. Benign fibroosseous lesions
may be metabolically active and thus mimic metastatic osseous disease in
children with underlying malignancies. Correlative CT or other anatomic
imaging can confirm the benign nature of these lesions.
Keywords: cortical desmoid fibroosseous defects fibrous cortical defect nonossifying fibroma nuclear imaging pediatric imaging PET/CT
Introduction
Benign fibroosseous lesions such as nonossifying fibromas, fibrous cortical
defects, and cortical desmoids are relatively common skeletal lesions that are
often discovered incidentally on radiographs of children and young adults
[1-6].
Nonossifying fibromas and fibrous cortical defects are most often located in
the metaphysis or diametaphyseal junction of the distal femur or proximal
tibia and are thought to be variants of the same pathologic process. These
lesions are classified as fibroxanthomas because of their histopathologic
features [4].
Nonossifying fibromas and fibrous cortical defects generally undergo
spontaneous regression over time and are rarely seen radiographically after
the second decade of life [2,
3]. During the involutional
phase, osteoblastic activity increases as the lesion is replaced by new bone.
The lesion initially appears sclerotic, and as healing occurs it eventually
disappears. Nonossifying fibromas can exhibit periods of substantial growth
and tend to take longer to regress than do fibrous cortical defects.
Cortical desmoids are small (1-3 cm) fibrous or fibroosseous defects
located on the posteromedial surface of the distal femur at the site of
attachment of the extensor tendinous fibers of the adductor magnus muscle
[4,
7,
8]. Also known as periosteal
desmoids and cortical avulsive injuries, these lesions occur in growing
children as a result of repetitive traction microavulsions with subsequent
fibroblastic response.
The conventional radiographic, CT, and MRI characteristics of nonossifying
fibromas, fibrous cortical defects, and cortical desmoids have been
extensively studied
[1-5].
Several studies have also described the appearance of nonossifying fibromas
and fibrous cortical defects on 99mTc methylene diphosphonate
(99mTc MDP) bone scintigraphic images
[6,
9,
10], but to our knowledge the
appearance of nonossifying fibromas, fibrous cortical defects, and cortical
desmoids on PET/CT images has not been reported.
This study was prompted by the observation of 18F-FDG-avid bone
lesions in children with underlying malignancy. These lesions were discovered
on PET/CT images and shown by the corresponding CT images or conventional
radiographs to be nonossifying fibromas, fibrous cortical defects, or cortical
desmoids. In this article, we describe the appearance of these benign bone
lesions on 34 PET/CT scans obtained in 14 children.
Materials and Methods
Patient Selection
From September 2004 until November 2005, we performed 675 PET/CT studies on
330 children with known or suspected malignancies. The PET/CT reports were
reviewed, and 32 patients were identified who had metabolically active lesions
that were suspected to be nonossifying fibromas, fibrous cortical defects, or
cortical desmoids, or that were of unclear cause. After institutional review
board approval, the PET/CT studies of these 32 patients were reviewed by one
pediatric radiologist.
PET/CT Scanning Parameters and Image Review
Whole-body PET/CT was performed on a Discovery LightSpeed PET/CT scanner
(GE Healthcare). Patients were instructed to fast for 4 or more hours before
receiving an injection of 18F-FDG (0.15 mCi/kg [55 MBq/kg] of body
weight) approximately 60 minutes before imaging. The CT portion of the
scanning was performed at a maximum of 90 mAs (adjusted for body weight), 120
kVp, and a slice thickness of 5 mm. No IV or oral contrast material was given.
PET images were obtained in two acquisitions: first from the pelvis cranially
to the skull vertex and then from the pelvis caudally to the toes. Images were
reconstructed in axial, coronal, and sagittal planes and were reviewed at an
Xeleris workstation (GE Healthcare).
From the PET images, we determined the maximum standardized uptake value
(SUV) of the lesion by drawing a region of interest around the area of
18F-FDG uptake and locating the region of maximum uptake. We
qualitatively assessed the 18F-FDG uptake of each lesion and
subjectively categorized it as follows: mild if the 18F-FDG uptake
of the lesion was judged to be
1.5 times that of the surrounding soft
tissue (Fig. 1A), moderate if
it was judged to be > 1.5 and < 3 times that of the surrounding soft
tissue (Fig. 2A), or intense if
it was judged to be 3 3 times that of the surrounding soft tissue
(Fig. 3A). For patients who
underwent multiple PET/CT scans over time, we recorded the qualitative
18F-FDG uptake and SUV measurements of the lesions on each
scan.
From the CT images, we recorded the anatomic site of the lesion (i.e.,
metaphyseal or diaphyseal), cortical or medullary involvement, and margin
distinctness. Reconstructed axial, coronal, or sagittal CT images or
conventional radiographs were analyzed using previously described
characteristic radiographic features
[2-4,
6]. Specifically, a fibrous
cortical defect was defined as a radiolucent, cortically based round to ovoid
lesion measuring less than 2.0 cm in greatest diameter, with sclerotic margins
and no associated soft-tissue abnormality. A nonossifying fibroma was defined
as a lesion with similar features but measuring 2.0 cm or larger in greatest
diameter with possible extension into the medullary cavity. For patients who
underwent multiple PET/CT examinations, we compared the measures of greatest
diameter from each scan and used the largest value to define the lesion as a
nonossifying fibroma or a fibrous cortical defect. Cortical desmoids were
defined as radiolucent, 1- to 3-cm cortical irregularities located on the
posteromedial surface of the distal femur with no associated soft-tissue mass
[2]. Conventional radiographs,
MR images, and 99mTc MDP bone scans obtained within 5 weeks of the
PET/CT examination were also reviewed by a study radiologist.
Results
Fourteen of the 32 patients whose PET/CT images were reviewed had lesions
that met our inclusion criteria. This cohort included 10 boys and four girls
whose mean age was 13.9 years (range, 6-19 years). Their primary diagnoses
included Ewing's sarcoma (n = 3); rhabdomyosarcoma (n = 2);
Hodgkin's lymphoma (n = 2); and one each of ganglioneuroblastoma,
nonrhabdomyosarcoma soft-tissue sarcoma, paraganglioma, osteosarcoma,
non-Hodgkin's lymphoma, epithelioid sarcoma, and aggressive fibromatosis.
Table 1 summarizes the
metabolic activity and sizes of the fibroosseous defects. Nine patients with
nonossifying fibromas or fibrous cortical defects underwent multiple PET/CT
examinations. Of those, six had lesions that showed no subjective change in
18F-FDG uptake but slightly varying SUVs, and three had lesions
that showed subjective increases in 18F-FDG uptake with little or
no change in the corresponding SUVs. Both patients who had cortical desmoids
underwent multiple PET/CT examinations: one lesion showed no change in the
subjective assessment of 18F-FDG uptake and little change in the
associated SUV, and the other showed decreased subjective 18F-FDG
uptake with no substantial change in the associated SUV. Considerable overlap
occurred in the SUVs for lesions placed in the three subjective
18F-FDG uptake categories and for lesions of varying size.
The greatest diameter measured in the group of 12 nonossifying fibromas and
fibrous cortical defects ranged from 1.3 to 5.4 cm (mean greatest diameter,
2.6 cm). Anatomic sites of the lesions included the distal femur (n =
7), proximal tibia (n = 3), and distal tibia (n = 2). Seven
lesions occurred near the diametaphyseal junction, three in the diaphysis, and
two in the metaphysis. All 12 lesions showed the characteristic radiographic
appearance previously described for nonossifying fibromas (Figs.
1B,
2B, and 3B) or fibrous cortical
defects.
In five of the 12 patients, radiographs confirmed the benign radiographic
features consistent with nonossifying fibroma and fibrous cortical defect.
Five of the 12 patients with a nonossifying fibroma or fibrous cortical defect
had 99mTc MDP bone scanning performed within 1 month of the PET/CT
study, in four of whom the scanning showed no abnormal tracer uptake at the
site of the lesion (Figs. 2C
and 2D), and in one of whom
minimally elevated 99mTc MDP uptake was seen.

View larger version (108K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2C 13-year-old boy with 3.2-cm nonossifying fibroma of left
distal femoral diaphysis. Anterior (C) and posterior (D) images
from technetium-99m methylene diphosphonate bone scintigraphy, which was
performed 1 week before PET/CT, show no activity at location of nonossifying
fibroma.
|
|

View larger version (109K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2D 13-year-old boy with 3.2-cm nonossifying fibroma of left
distal femoral diaphysis. Anterior (C) and posterior (D) images
from technetium-99m methylene diphosphonate bone scintigraphy, which was
performed 1 week before PET/CT, show no activity at location of nonossifying
fibroma.
|
|
MR images of the lesion site were available for one patient with
nonossifying fibroma. MRI showed the lesion to be centrally hypointense on
T1-weighted images, with a mixed internal signal on T2-weighted images, and a
hypointense rim on both T1 and T2 images. This lesion showed moderate
heterogeneous enhancement with gadolinium.
Both cortical desmoids showed characteristic radiographic features of these
lesionsthat is, saucer-shaped radiolucent cortical irregularity, the
lack of an outer margin, and a location at the posteromedial aspect of the
distal femoral metaphysis at the attachment of the adductor magnus tendon
(Fig. 4A, 4B). A corresponding
conventional radiograph, 99mTc MDP bone scan, and MR image were
available for one patient. The radiograph showed a subtle cortical
radiolucency at the distal posterior femoral metaphysis. The 99mTc
MDP bone scan showed no increased activity associated with the lesion. The MR
image revealed a cortically based lesion without soft-tissue involvement that
had a bright center and a dark peripheral margin on T2-weighted images and
that showed central enhancement in a dark peripheral margin on
contrast-enhanced T1-weighted images.
Discussion
Our results indicate that nonossifying fibromas, fibrous cortical defects,
and cortical desmoids may appear metabolically active on PET. In addition,
18F-FDG PET may be a more sensitive method for detecting and
characterizing the metabolic activity of benign fibroosseous lesions than
99mTc MDP bone scintigraphy. In a small series (n = 10)
reported by Greyson and Pang
[6], the 99mTc MDP
bone scintigraphy appearance of nonossifying fibromas and fibrous cortical
defects varied with the developmental stage of the lesions. Inactive or healed
lesions showed no uptake of 99mTc MDP on three-phase bone scans,
while those in the healing or involutional stage showed faint to moderate
uptake on delayed imaging.
In our study, five patients had corresponding 99mTc MDP bone
scans. Of those, four did not show increased uptake of 99mTc MDP.
These included two lesions that showed moderate 18F-FDG uptake and
two that showed mild 18F-FDG uptake on PET/CT. In the remaining
patient, the nonossifying fibroma with mild uptake of 99mTc MDP
showed moderate 18F-FDG uptake.
We found no association between the size of lesions and the subjective
assessment of 18F-FDG uptake or the SUV. Among the 11 patients who
had serial PET/CT examinations, no significant change was seen in SUVs in
those lesions that showed subjective changes in 18F-FDG uptake over
time. Furthermore, considerable overlap occurred in SUVs for lesions in the
three subjective 18F-FDG uptake categories. Although our sample
size is small, the variability in SUV measurements among lesions that were
determined qualitatively to have similar or very different 18F-FDG
uptake suggests a poor correlation between the subjective assessment of
metabolic activity in the lesions and this quantitative parameter.
The reported incidence of nonossifying fibromas and fibrous cortical
defects is 20-40%, and that of cortical desmoids is approximately 11% in boys
and 3.6% in girls
[1-3].
Although we found a much lower incidence of these lesions (3.6% for
nonossifying fibromas and fibrous cortical defects and 0.6% for cortical
desmoids) in our cohort, our assessment was based on metabolic activity.
Therefore, only lesions that showed 18F-FDG uptake were included.
In addition, the intense physiologic uptake of 18F-FDG typically
observed around the physes of children's long bones may have obscured small
lesions and could also, at least partially, explain why we identified mostly
diametaphyseal (n = 5) and diaphyseal (n = 3) lesions and
few (n = 2) metaphyseal lesions.
The correlative CT performed during PET/CT accurately located and
characterized these lesions, thereby dispelling concerns of osseous metastatic
disease and obviating additional diagnostic procedures. Although CT is not
typically indicated for evaluation, it can provide additional detailed
information about the integrity of the cortex of the lesion and whether an
associated soft-tissue component is present. CT can also help determine
whether a pathologic fracture has occurred
[2-4].
Therefore, information gained from the CT assessment of the lesion can guide
further management and help determine whether additional characterization is
needed.
We have shown that the metabolic activity of nonossifying fibromas, fibrous
cortical defects, and cortical desmoids is probably independent of lesion size
and varies among patients and over time, as indicated by their
18F-FDG uptake on PET. This finding is consistent with the natural
history of these fibroosseous lesions. Our findings also suggest that PET/CT
is more sensitive than conventional 99mTc MDP bone scintigraphy in
the detection of these benign lesions. This result is important to consider
when PET or PET/CT is performed on children with an underlying malignancy
because the PET appearance of these lesions can mimic bone metastatic disease.
These fibroosseous lesions have classic radiographic features; therefore, the
information obtained either from the CT component of the PET/CT examination or
from conventional radiography is invaluable for characterizing these lesions
and determining whether further imaging or biopsy is necessary.
References
- Caffey J. On fibrous defects in cortical walls of growing tubular
bones: their radiologic appearance, structure, prevalence, natural course, and
diagnostic significance. Adv Pediatr1955; 7:13
-51[Medline]
- Brant WE, Helms CA. Fundamentals of diagnostic
radiology, 2nd ed. Philadelphia, PA: Lippincott Williams &
Wilkins, 1999: 969-971
- Betsy M, Kupersmith LM, Springfield DS. Metaphyseal fibrous
defects. J Am Acad Orthop Surg 2004;12
: 89-95[Abstract/Free Full Text]
- Smith SE, Kransdorf MJ. Primary musculoskeletal tumors of fibrous
origin. Semin Musculoskelet Radiol 2000;4
: 73-88[CrossRef][Medline]
- Jee WH, Choe BY, Kang HS, et al. Nonossifying fibroma:
characteristics at MR imaging with pathologic correlation.
Radiology 1998;209
: 197-202[Abstract/Free Full Text]
- Greyson ND, Pang S. The variable bone scan appearances of
nonosteogenic fibroma of bone. Clin Nucl Med1981; 6:242
-245[CrossRef][Medline]
- Burrows PE, Greenberg ID, Reed MH. The distal femoral defect:
technetium-99m pyrophosphate bone scan results. J Can Assoc
Radiol 1982; 33:91
-93[Medline]
- Jung C, Choi YY, Cho S, Park KC. Symptomatic cortical desmoids
detected on knee SPECT. Clin Nucl Med2002; 27:437
-438[CrossRef][Medline]
- Brenner RJ, Hattner RS, Lillien DL. Scintigraphic features of
nonosteogenic fibroma. Radiology 1979;131
: 727-730[Abstract]
- Gilday DL, Ash JM. Benign bone tumors. Semin Nucl
Med 1976; 6:33
-46[Medline]

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?